Comparative Pharmacology
Head-to-head clinical analysis: FETZIMA versus KHEDEZLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FETZIMA versus KHEDEZLA.
FETZIMA vs KHEDEZLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fetzima (levomilnacipran) is a selective serotonin and norepinephrine reuptake inhibitor (SNRI). It inhibits the reuptake of serotonin and norepinephrine, with approximately 2-fold higher potency for norepinephrine reuptake inhibition, which enhances neurotransmission in the central nervous system.
Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that selectively inhibits the reuptake of serotonin and norepinephrine, thereby enhancing neurotransmission in the central nervous system.
20 mg orally once daily for 2 days, then 40 mg once daily for 2 days, then 80 mg once daily for 2 days, then 120 mg once daily; maximum dose 120 mg/day.
20 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours for levomilnacipran; at steady state, half-life supports once-daily dosing without extensive accumulation.
Approximately 11 hours; supports once-daily dosing; steady state reached within 3 days.
Primarily renal (approximately 65% as unchanged levomilnacipran and 25% as N-desmethyllevomilnacipran); fecal excretion accounts for ~8%.
Primarily renal (70-80% as unchanged desvenlafaxine), with minor fecal elimination (approx. 5%).
Category C
Category C
SNRI Antidepressant
SNRI Antidepressant